Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer.

Trial Profile

Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2012 Planned number of patients changed from 30 to 78 as reported by European Clinical Trials Database.(Parent trial: EudraCT2008-006425-14).
    • 07 Jul 2012 Planned number of patients changed from 30 to 78 as reported by European Clinical Trials Database.(Parent trial: EudraCT2008-006425-14).
    • 09 Jun 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database (Extension trial: EudraCT2011-001309-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top